Berotralstat, sold under the brand name Orladeyo, is a medication used to prevent attacks of hereditary angioedema (HAE) in people aged twelve years and older. The most common side effects include abdominal pain, vomiting, diarrhea, back pain, and heartburn. Berotralstat was approved for medical use in the United States in December 2020, and in the European Union in April 2021.
Attributes | Values |
---|
rdf:type
| |
rdfs:label
| - Berotralstat (en)
- Berotralstat (de)
- ベロトラルスタット (ja)
|
rdfs:comment
| - Berotralstat, sold under the brand name Orladeyo, is a medication used to prevent attacks of hereditary angioedema (HAE) in people aged twelve years and older. The most common side effects include abdominal pain, vomiting, diarrhea, back pain, and heartburn. Berotralstat was approved for medical use in the United States in December 2020, and in the European Union in April 2021. (en)
- Berotralstat, verkauft unter dem Markennamen Orladeyo, ist ein Medikament zur Vorbeugung von Attacken des hereditären Angioödems bei Menschen ab zwölf Jahren. Berotralstat wurde im Dezember 2020 in den Vereinigten Staaten von der FDA für die medizinische Anwendung zugelassen. (de)
- ベロトラルスタット(Berotralstat)は、12歳以上の患者の(HAE)の発作を予防するために使用される血漿カリクレイン阻害薬である。 (ja)
|
foaf:depiction
| |
dcterms:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
Link from a Wikipage to an external page
| |
sameAs
| |
dbp:wikiPageUsesTemplate
| |
thumbnail
| |
ATC suffix
| |
ATC prefix
| |
c
| |
CAS number
| |
ChemSpiderID
| |
class
| |
DrugBank
| |
F
| |
H
| |
index2 label
| |
IUPAC name
| |
KEGG
| |
legal US
| |
n
| |
O
| |
PubChem
| |
routes of administration
| |
SMILES
| |
StdInChI
| |
StdInChIKey
| - UXNXMBYCBRBRFD-MUUNZHRXSA-N (en)
|
synonyms
| |
tradename
| |
UNII
| |
has abstract
| - Berotralstat, sold under the brand name Orladeyo, is a medication used to prevent attacks of hereditary angioedema (HAE) in people aged twelve years and older. The most common side effects include abdominal pain, vomiting, diarrhea, back pain, and heartburn. Berotralstat was approved for medical use in the United States in December 2020, and in the European Union in April 2021. (en)
- Berotralstat, verkauft unter dem Markennamen Orladeyo, ist ein Medikament zur Vorbeugung von Attacken des hereditären Angioödems bei Menschen ab zwölf Jahren. Berotralstat wurde im Dezember 2020 in den Vereinigten Staaten von der FDA für die medizinische Anwendung zugelassen. (de)
- ベロトラルスタット(Berotralstat)は、12歳以上の患者の(HAE)の発作を予防するために使用される血漿カリクレイン阻害薬である。 (ja)
|
DailyMedID
| |
legal CA
| |
legal EU
| |
licence EU
| |
prov:wasDerivedFrom
| |
page length (characters) of wiki page
| |
alternative name
| |
CAS number
| - 1809010-50-1
- 1809010-52-3
|
DrugBank
| |
FDA UNII code
| |
KEGG
| |
PubChem
| |
class
| |
foaf:isPrimaryTopicOf
| |
is Link from a Wikipage to another Wikipage
of | |
is Wikipage redirect
of | |
is foaf:primaryTopic
of | |